NODAL'MARGINAL'ZONE'LYMPHOMA'–'A'SINGLE'CENTER'EXPERIENCE'
POSTER'16'
ALONG'9'YEARS'
'
Maria! Eduarda! Couto1,! Carolina! Sales2,! Isabel! Oliveira1,! Nelson! Domingues1,! Luisa! Viterbo1,! Angelo!
Martins1,! Ilídia! Moreira1,! Ana! EspiritoJSanto1,! Sérgio! Chacim1,! Cláudia! Moreira1,! Dulcineia!
Pereira1!and!José!Mariz1!
!
(1)OncoUhematology!Service,!Instituto!Português!de!Oncologia!do!Porto,!F.G.,!E.P.E.,!Porto,!Portugal,!
(2)Oncology!Service,!Hospital!Dr.!Nélio!Mendonça,!Funchal,!Portugal!
!
Nodal!marginal!zone!lymphomas!(NMZL)!have!low!frequency!and!usually!show!an!indolent!
course.!This!study!aims!to!characterize!the!demography!of!patients!diagnosed!with!NMZL!in!
one! hospital.! This! is! a! retrospective! and! unicenter! study.! Data! were! collected! from! the!
clinical!files!of!patients!diagnosed!along!9!years!(2011J2019),!followed!up!until!august!2020.!
A!total!of!37!patients!were!identified,!with!a!median!age!of!71!30J86!years,!54.1%!of!them!
females.!From!those,!21.6%!were!in!Ann!Harbor!stage!I,!2.7%!in!stage!III!and!75.7%!in!stage!
IV.! B! symptoms! were! identified! in! 37.8%.! All! cases! were! ECOG! ≤! 2! (only! 2! were! ECOG! 2).!
67.5%!were!MALTJIPI!1!or!2.!
One! patient! did! not! need! any! treatment,! 73%! did! only! the! first! line! therapy,! 16.2%! did! 2!
lines,!5.4%!did!3!lines!and!2.7%!did!4!treatment!lines.!
ThirtyJtree! did! immunochemotherapy! in! the! first! line! therapy! (1! was! also! submitted! to!
surgery! and! another! one! to! radiotherapy)! and! 3! did! only! radiotherapy.! The! complete!
response!rate!(CR)!was!72.2%,!partial!response!(PR)!rate!was!13.9%,!2.8%!had!stable!disease,!
8.3%!had!disease!progression!and!2.8%!were!not!evaluated!(a!palliative!patient).!
For! those! who! achieved! a! response! (86%),! 19%! relapsed! (6).! The! progression! free! survival!
was!13!months!2J63.!Along!the!second!line!treatment,!one!was!submitted!to!splenectomy,!
3!did!chemotherapy!and!2!remained!in!surveillance!(asymptomatic).!
From!the!9!patients!who!did!second!line!treatment!(3!in!relapse),!the!CR!rate!was!44.4%,!PR!
was!11.1%!and!44.4%!progressed.!
None! of! the! 3! patient! who! did! a! third! line! therapy! achieved! a! response.! One! case! did! an!
additional! fourth! line! therapy! with! radiotherapy! and! rituximab,! obtaining! a! complete!
response.!
Four! patients! died! until! the! end! of! this! study,! 2! with! active! disease.! The! median! overall!
survival!was!not!achieved,!but!the!mean!was!89.6!months!(IC!95%!81J98).!The!event!free!
survival!time!was!23!months!0J95.!
NMZL! is! an! indolent! disease! manageable! in! a! great! number! of! patients! with! the! large!
therapeutic! arsenal! available! (efficient! and! durable),! as! shown! in! this! single! center!
experience.!However,!the!therapeutic!options!are!still!scarce!for!older!and!fragile!patients.!
! !
SCIENTIFIC PROGRAMME
SESSION I
HODGKIN’S DISEASE
DEBATE I
IS THERE STILL A ROLE
FOR COMBINED MODALITY
THERAPY FOR EARLY
STAGE CHL?
SESSION II
T-CELL LYMPHOMA
ROUNDTABLE I
FUTURE DIRECTIONS IN
T-CELL LYMPHOMA
SESSION III
FOLLICULAR LYMPHOMA
DEBATE II
CAN WE AVOID
CHEMOTHERAPY IN
THE MANAGEMENT OF
FOLLICULAR LYMPHOMA?
SESSION IV
RARE LYMPHOMAS –
MARGINAL ZONE
LYMPHOMA AND
WALDENSTRÖM M
ACROGLOBULINEMIA
ROUNDTABLE II – WHERE
TO GO IN RARE B-CELL
LYMPHOMAS
SESSION V
MANTLE CELL LYMPHOMA
SESSION VI
DIFFUSE LARGE B-CELL
LYMPHOMA
DEBATE III
DO WE STILL NEED ASCT
IN MCL?
SESSION VII
NOVEL THER APEUTIC
CONCEPTS IN B-CELL
LYMPHOMAS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES